Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
placebo on the time to occurrence of a composite cardiovascular outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, hospitalization or urgent visit due to heart failure) and a composite renal outcome (end-stage kidney disease, 40% sustained decline in eGFR, cardiovascular death or renal death) in 10,000 individuals with atherosclerotic cardiovascular disease and/or CKD
For example, a plan may place a drug on a pharmacy formulary with a tier-2 copay, whereas the same drug administered by infusion might require step therapy to a lower-cost alternative under medical policies (with even 20% coinsurance after deductible for the patient)
Compliance in every shipment
Biomarkers of inflammation and oxidative stress in ophthalmic disorders
US$ 21.15
US$ 27.22
US$ 27.42
US$ 20.74
US$ 26.82
US$ 24.32
